Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Read More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Press Releases||View All »|
02/23/17Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
|Lee M. Stern, CFA|
The Trout Group
Phone: (646) 378-2922